Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B.
Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version.
This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare production, while taking into consideration the maximum expenditure (budget) allowed by the government or the health system regulator.
The paper seeks to address two perennial policy and practical discussions in the UK National Health Service (NHS) (and elsewhere): how to cope with financial austerity; and the opportunity costs of reimbursing new health technologies.
Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.
Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.
It is often argued that the demands for increased healthcare expenditure arising from an ageing population, advancing technologies, and increasing expectations, warrant higher healthcare budgets. Professor Stephen Birch argues that this reactive approach is not sustainable, and that the perceived mismatch between resources and demand is due to poor health service planning. In this briefing, based on an OHE lunchtime seminar, Professor Birch presents a framework to re-focus planning models on population needs.
The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.